Genotype Diagnostics
Genotype Diagnostics is a molecular diagnostic testing and precision medicine company focused on genetic testing across cancer care, prenatal health, and mental health.
Profile
Provides genetic testing for cancer risk, prenatal health, and mental health treatment guidance.
Genotype Diagnostics is a molecular diagnostic testing and precision medicine company focused on genetic testing across cancer care, prenatal health, and mental health. Founded in [year not disclosed in dossier], the company has established itself as a key player in the direct-to-consumer genetic testing market, competing with larger firms like Quest Diagnostics and Myriad Genetics. Genotype Diagnostics offers a range of branded genetic tests, including those for hereditary cancer risk, prenatal screening, and pharmacogenomics for mental health treatments.
The company's financial trajectory shows modest growth, with Q1 2026 revenue of $200.4 million, up 2% year-over-year, though test volumes remained flat. Notably, their Cancer Care Continuum segment grew 13% in test volume, while Prenatal Health declined 12%. The company recently launched Precise MRD, an ultrasensitive assay for cancer monitoring, and received FDA approval for MyChoice CDx as a companion diagnostic for ovarian cancer treatment. Genotype Diagnostics faces challenges in balancing growth across its segments while investing in new product launches like Precise MRD, which is expected to drive future revenue.
Who buys this
- Oncology patients and healthcare providers
- Expecting parents and obstetricians
- Psychiatrists and mental health clinicians
- Direct-to-consumer health enthusiasts
Strengths and what to watch
Strengths
- FDA-approved companion diagnostic (MyChoice CDx) for ovarian cancer treatment
- Double-digit growth in Cancer Care Continuum and Mental Health test volumes
- Launch of Precise MRD, a promising ultrasensitive assay for cancer monitoring
Watch for
- 12% decline in Prenatal Health test volumes year-over-year
- GAAP net loss of $34.1 million in Q1 2026
- Dependence on successful commercialization of new products like Precise MRD
Recent moves
Key Information
- Headquarters
- New York, New York
Frequently Asked Questions
What is Genotype Diagnostics?
Genotype Diagnostics provides genetic testing for cancer risk, prenatal health, and mental health treatment guidance. The company offers FDA-approved tests like MyChoice CDx for ovarian cancer and recently launched Precise MRD, an ultrasensitive cancer monitoring assay. Their services cater to patients, clinicians, and direct-to-consumer health markets.
What genetic tests does Genotype Diagnostics offer?
Genotype Diagnostics provides hereditary cancer risk tests, prenatal health screenings, and pharmacogenomic tests for mental health treatments. Their FDA-approved MyChoice CDx helps guide ovarian cancer treatment, while Precise MRD offers advanced cancer monitoring. Test volumes show 13% growth in cancer care but 12% decline in prenatal screenings.
How accurate is Genotype Diagnostics' cancer risk testing?
Genotype Diagnostics' cancer tests include FDA-approved companion diagnostics like MyChoice CDx for ovarian cancer. Their new Precise MRD assay provides ultrasensitive monitoring, though specific accuracy rates aren't disclosed. The company's cancer care segment grew 13% in test volumes, indicating clinical adoption of their offerings.
Does Genotype Diagnostics offer prenatal genetic screening?
Yes, Genotype Diagnostics provides prenatal health genetic screenings, though this segment declined 12% year-over-year. Their tests help expecting parents and obstetricians assess genetic risks. The company continues offering these services alongside growing areas like cancer diagnostics and mental health pharmacogenomics.
What's new with Genotype Diagnostics' mental health testing?
Genotype Diagnostics offers pharmacogenomic tests to guide mental health treatments, analyzing how genetics affect medication response. While financial details aren't specified, the company groups this with growing service lines. Their focus remains on clinically actionable genetic insights across cancer, prenatal, and mental health domains.
How does Genotype Diagnostics compare to Quest Diagnostics?
Genotype Diagnostics specializes in genetic testing for cancer, prenatal, and mental health, while Quest offers broader lab services. Genotype's niche includes FDA-approved diagnostics like MyChoice CDx and novel assays like Precise MRD. The company reported $200.4M Q1 2026 revenue, showing modest 2% growth year-over-year.
Sources
- investor.myriad.com — Q1 2026 financial results and product launches
- pmc.ncbi.nlm.nih.gov — Context on direct-to-consumer genetic testing market
- www.prnewswire.com — Competitive context from Quest Diagnostics results
- ir.questdiagnostics.com — Additional competitive context from Quest Diagnostics